Login / Signup

Antiviral agents and therapeutics against respiratory viruses.

Ralph A TrippDavid E Martin
Published in: Expert opinion on investigational drugs (2024)
Antiviral drugs being developed assess different mechanisms of action to combat viruses and other delivery routes (i.e. oral, inhalation, or parenteral). The associated clinical trials address the impact on disease while determining the appropriate dosage levels for further investigation in Phase III. A robust pipeline of agents is necessary to meet the global need for effective antiviral therapeutics.
Keyphrases
  • phase iii
  • clinical trial
  • open label
  • small molecule
  • phase ii
  • double blind
  • randomized controlled trial
  • placebo controlled
  • study protocol
  • respiratory tract